Hair loss on GLP-1 drugs is real but uncommon. On the Wegovy label it was reported in 3.3% of adults on 2.4 mg versus 1% on placebo, and on the Zepbound label in 4% to 5% versus 1%, mostly in women. It usually looks like telogen effluvium: diffuse shedding a few months after rapid weight loss.[4][5]
“Is Ozempic making my hair fall out?” is one of the most-searched GLP-1 side-effect questions — and the honest answer is more reassuring than the headlines. In most cases the culprit isn’t the drug directly; it’s the rapid weight loss the drug produces, which triggers a well-understood, temporary kind of shedding. Here’s what the evidence actually shows.
What kind of hair loss this is
The pattern reported with GLP-1 medications is telogen effluvium: a diffuse, all-over thinning (not bald patches) that happens when a stressor pushes a large fraction of hair follicles into their resting/shedding phase at once. Any significant physiological stress — major illness, childbirth, crash dieting, big surgery — can do it, and rapid weight loss is a classic trigger. A review of hair health after bariatric (weight-loss) surgery ties the telogen effluvium seen after those operations to the weight loss itself, plus low calorie and protein intake, micronutrient deficiencies and anesthesia.[1] Weight loss is the leading explanation for GLP-1 shedding too, but not the only one: a 2026 scoping review found the evidence conflicting, with risk that may rise with longer use, greater weight loss and higher doses, and proposed contributions from changes in the fat layer of the skin and from hormones.[3]
The timing tells the story
Telogen effluvium is delayed: follicles take time to cycle into the shedding phase, so diffuse shedding typically appears about 3 to 4 months after the triggering event,[6] often right when people are seeing their best scale results. That delay is a clue to the mechanism, and it’s also why it’s reassuring: acute telogen effluvium is self-limiting.[7] Once weight stabilizes and the stressor passes, the follicles re-enter their growth phase and hair generally regrows over the following months.
| Question | What the evidence supports |
|---|---|
| How common is it? | Wegovy 2.4 mg: 3.3% vs 1% on placebo; Zepbound: 4% to 5% vs 1% |
| Who gets it most? | Women (Zepbound: 7.1% of women vs 0.5% of men) |
| Is it the drug damaging follicles? | Mostly linked to weight loss (telogen effluvium); other mechanisms unproven |
| Bald patches or diffuse thinning? | Diffuse, all-over thinning |
| When does it show up? | Delayed: about 3 to 4 months after the trigger |
| Is it permanent? | Usually no: acute telogen effluvium is self-limiting |
What you can actually do about it
Because the trigger is the pace of weight loss and nutritional adequacy, the levers follow directly: aim for a steadier rate of loss rather than the fastest possible drop, keep protein intake adequate (especially important on GLP-1 drugs, which blunt appetite), and make sure iron, zinc and other hair-relevant nutrients aren’t running low — the same deficiencies flagged in the post-bariatric hair research.[1] If shedding is severe, prolonged, or patchy rather than diffuse, that’s worth a dermatology visit to rule out other causes.
The honest bottom line
Hair loss on GLP-1 medications is real, but it’s usually telogen effluvium driven by rapid weight loss — diffuse, delayed by a few months, and typically reversible once your weight stabilizes.[2][3] It affects a small minority (3.3% vs 1% on placebo on Wegovy 2.4 mg),[4] and the practical response — lose weight at a steadier pace, protect your protein and micronutrients — addresses the actual mechanism. For the side effects that did dominate the trials, see our GI side-effects timeline, and for the muscle-and-lean-mass question, our lean-mass guide.